Patent search ap:("Merck Sharp & Dohme Corp.") AND inv:"Jae-Hun Kim" Page 1

1.

发明申请
HETEROCYCLIC COMPOUNDS AS HIV PROTEASE INHIBITORS 审中-公开

公开(公告)号：US20200069691A1

公开(公告)日：2020-03-05

申请号：US16461899

申请日：2017-12-19

Applicant: Merck Sharp & Dohme Corp.

Inventor： Brian McKittrick , John P. Caldwell , John McCauley , Henry Vaccaro , Tin-Yau Chan , Hyunjin Kim , Elizabeth Smith , Liwu Hong , Tanweer Khan , Shihong Ying , Hongwu Wang , Peter D. Williams , Jae-Hun Kim , M. Brad Nolt , Maryann Caplen

IPC: A61K31/519 , A61K45/06 , C07D487/04 , A61K31/4985 , C07D519/00 , C07D413/14 , A61K31/496 , C07D498/04 , C07D403/14 , C07D413/10 , C07D498/14 , A61K31/5383 , A61K31/4178 , A61K31/4188 , A61K31/424 , A61K31/4355 , A61K31/429 , C07D513/04 , A61P31/18

Abstract: The present invention is directed to compounds of Formula I pharmaceutical compositions comprising the same, and their use in the inhibition of HIV protease, the inhibition of HIV replication, the prophylaxis of infection by HIV, the treatment of infection by HIV, and the prophylaxis, treatment, and delay in the onset or progression of AIDS.

2.

发明申请
PIPERAZINE-SUBSTITUTED [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES 有权
Title translation: 哌嗪取代[1,2,4]三唑[1,5-C]喹唑啉-5-胺化合物，具有A2A拮抗剂性质

公开(公告)号：US20160194330A1

公开(公告)日：2016-07-07

申请号：US14655572

申请日：2013-12-20

Applicant: Amjad ALI , Michael Man-Chu LO , Yeon-Hee LIM , Andrew STAMFORD , Rongze KUANG , Paul TEMPEST , Younong YU , Michael BERLIN , Pauline TING , Gang ZHOU , Tao YU , Christopher BOYCE , Joseph Michael KELLY , Jayaram TAGAT , Junying ZHENG , Xianhai HUANG , Wei ZHOU , Jae-Hun KIM , Nicolas ZORN , Dong XIAO , Gioconda V. GALLO , Walter WON , Heping WU , Rajan ANAND , MERCK SHARP & DOHME CORP.

Inventor： Amjad Ali , Michael Man-Chu Lo , Yeon-Hee Lim , Andrew Stamford , Rongze Kuang , Paul Tempest , Younong Yu , Michael Berlin , Pauline Ting , Gang Zhou , Tao Yu , Christopher Boyce , Joseph Michael Kelly , Jayaram R. Tagat , Junying Zheng , Xianhai Huang , Wei Zhou , Jae-Hun Kim , Nicolas Zorn , Dong Xiao , Gioconda V. Gallo , Walter Won , Heping Wu , Rajan Anand , Qiaolin Deng

IPC: C07D487/04 , C07D487/18 , C07D487/08 , C07D513/04

CPC classification number: C07D487/04 , C07D487/08 , C07D487/18 , C07D513/04

Abstract: Disclosed are compounds of Formula A: (structurally represented) where “RG1”, “RG2a”, “RG4”, “RG5”, “MG1”, “n” and “m” are defined herein which compounds are antagonists of A2A receptor. Disclosed herein also are uses of the compounds described herein as antagonists of the A2a receptor in the potential treatment or prevention of neurological disorders and diseases in which A2A receptors are involved. Disclosed herein also are pharmaceutical compositions comprising these compounds and uses of these pharmaceutical compositions.

Abstract translation: 公开了式A化合物（结构表示），其中“RG1”，“RG2a”，“RG4”，“RG5”，“MG1”，“n”和“m”在本文中定义为哪些化合物是A2A受体的拮抗剂。本文还公开了本文所述的化合物作为A2a受体的拮抗剂的潜在治疗或预防涉及A2A受体的神经障碍和疾病的用途。本文还公开了包含这些化合物的药物组合物和这些药物组合物的用途。

3.

发明授权
Heterobicyclo-substituted [1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with A2A anatagonist properties 有权

公开(公告)号：US10011615B2

公开(公告)日：2018-07-03

申请号：US15423238

申请日：2017-02-02

Applicant: Merck Sharp & Dohme Corp.

Inventor： Amjad Ali , Michael Man-Chu Lo , Yeon-Hee Lim , Andrew Stamford , Rongze Kuang , Paul Tempest , Younong Yu , Xianhai Huang , Timothy J. Henderson , Jae-Hun Kim , Christopher Boyce , Pauline Ting , Junying Zheng , Edward Metzger , Nicolas Zorn , Dong Xiao , Gioconda V. Gallo , Walter Won , Heping Wu , Qiaolin Deng

IPC: A01N43/00 , A01N43/46 , C07D519/00 , C07D487/04

CPC classification number: C07D519/00 , C07D487/04

Abstract: Disclosed are compounds of Formula G1: where “RG3”. “Rd1” to “Rd4”, “n”, “m”, “p”, “W”, “X”, “Y”, and “Z” are defined herein, which compounds are antagonists of A2A receptor. Disclosed herein also are uses of the compounds described herein as antagonists of the A2A receptor in the potential treatment or prevention of neurological disorders and diseases in which A2A receptors are involved. Disclosed herein also are pharmaceutical compositions comprising these compounds and uses of these pharmaceutical compositions.

4.

发明授权
Preparation and use of 3-pyridyl substituted-6,6-difluoro bicyclic himbacine derivatives as par-1 receptor antagonists 有权

公开(公告)号：US09808473B2

公开(公告)日：2017-11-07

申请号：US14912315

申请日：2014-08-18

Applicant: Merck Sharp & Dohme Corp.

Inventor： James Francis Dropinski , Milana Maletic , Jae-Hun Kim , Deyou Sha

IPC: A61K31/34 , A61K31/60 , A61K45/06 , A61K31/4365 , A61K31/444 , C07D405/14 , C07D409/14 , C07D409/04 , A61K31/343

CPC classification number: A61K31/60 , A61K31/343 , A61K31/4365 , A61K31/444 , A61K45/06 , C07D405/14 , C07D409/04 , C07D409/14 , A61K2300/00

Abstract: The present invention relates to bicyclic himbacine derivatives of the formula or a pharmaceutically acceptable salt thereof wherein: R1 is halo; —CN; alkyl; cycloalkyl; alkoxy; phenyl, which is optionally substituted one or twice independently by alkyl, halo, or —CN; or a thiophene ring, which is optionally substituted once or twice independently by alkyl. The compounds of the invention are effective inhibitors of the PAR-1 receptor. The inventive compounds may be used for the treatment or prophylaxis of disease states such as ASC, secondary prevention of myocardial infarction or stroke, or PAD.

5.

发明授权
Piperazine-substituted [1,2,4]triazolo[1,5-C]quinazolin-5-amine compounds with A2A antagonist properties 有权

公开(公告)号：US09676780B2

公开(公告)日：2017-06-13

申请号：US14655572

申请日：2013-12-20

Applicant: MERCK SHARP & DOHME CORP. , Amjad Ali , Michael Man-Chu Lo , Yeon-Hee Lim , Andrew Stamford , Rongze Kuang , Paul Tempest , Younong Yu , Michael Berlin , Pauline Ting , Gang Zhou , Tao Yu , Christopher Boyce , Joseph Michael Kelly , Jayaram R. Tagat , Junying Zheng , Xianhai Huang , Wei Zhou , Jae-Hun Kim , Nicolas Zorn , Dong Xiao , Gioconda V. Gallo , Walter Won , Heping Wu , Rajan Anand , Qiaolin Deng

Inventor： Amjad Ali , Michael Man-Chu Lo , Yeon-Hee Lim , Andrew Stamford , Rongze Kuang , Paul Tempest , Younong Yu , Michael Berlin , Pauline Ting , Gang Zhou , Tao Yu , Christopher Boyce , Joseph Michael Kelly , Jayaram R. Tagat , Junying Zheng , Xianhai Huang , Wei Zhou , Jae-Hun Kim , Nicolas Zorn , Dong Xiao , Gioconda V. Gallo , Walter Won , Heping Wu , Rajan Anand , Qiaolin Deng

IPC: C07D487/04 , A61K31/519 , C07D487/08 , C07D487/18 , C07D513/04

CPC classification number: C07D487/04 , C07D487/08 , C07D487/18 , C07D513/04

Abstract: Disclosed are compounds of Formula A: (structurally represented) where “RG1”, “RG2a”, “RG4”, “RG5”, “MG1”, “n” and “m” are defined herein which compounds are antagonists of A2A receptor. Disclosed herein also are uses of the compounds described herein as antagonists of the A2a receptor in the potential treatment or prevention of neurological disorders and diseases in which A2A receptors are involved. Disclosed herein also are pharmaceutical compositions comprising these compounds and uses of these pharmaceutical compositions.

6.

发明申请
HETEROCYCLE-SUBSTITUTED TETRACYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES 有权
Title translation: 杂环取代的四环化合物及其用于治疗病毒性疾病的方法

公开(公告)号：US20150335648A1

公开(公告)日：2015-11-26

申请号：US14761256

申请日：2013-12-31

Applicant: MERCK SHARP & DOHME CORP.

Inventor： Wensheng Yu , Ling Tong , Joseph A. Kozlowski , Oleg Selyutin , Lei Chen , Jae-Hun Kim , Deyou Sha , Razia Rizvi , Bandarpalle Shankar , Bin Hu , Bin Zhong , Dahai Wang , Jinglai Hao , Wei Wei , Tao Ji , Shuai Zan

IPC: A61K31/5365 , C07D498/04 , C07D513/04 , A61K45/06

CPC classification number: A61K31/5365 , A61K31/4985 , A61K31/7056 , A61K31/7072 , A61K45/06 , C07D498/04 , C07D513/04 , Y02A50/385 , Y02A50/389 , A61K2300/00

Abstract: The present invention relates to novel Heterocycle-Substituted Tetracyclic Compounds of Formula (I): (I) and pharmaceutically acceptable salts thereof, wherein A, A′, R2 R3, R4 and R are as defined herein. The present invention also relates to compositions comprising at least one Heterocycle-Substituted Tetracyclic Compound, and methods of using the Heterocycle-Substituted Tetracyclic Compounds for treating or preventing HCV infection in a patient.

Abstract translation: 本发明涉及式（I）的新型杂环取代的四环化合物：（I）及其药学上可接受的盐，其中A，A'，R 2 R3，R4和R如本文所定义。本发明还涉及包含至少一种杂环取代的四环化合物的组合物，以及使用杂环取代的四环化合物治疗或预防患者HCV感染的方法。

7.

发明授权
Heterocycle-substituted tetracyclic compounds and methods of use thereof for the treatment of viral diseases 有权

公开(公告)号：US10646494B2

公开(公告)日：2020-05-12

申请号：US16326039

申请日：2017-08-14

Applicant: Merck Sharp & Dohme Corp.

Inventor： Wensheng Yu , Ling Tong , Joseph A. Kozlowski , Craig A. Coburn , De-Yi Yang , Deyou Sha , Jae-Hun Kim , Michael Dwyer , Kartik M Keertikar , Bin Hu , Bin Zhong , Jinglai Hao , Dahai Wang

IPC: C07D498/04 , A61K31/5365 , C07D519/00 , C07D513/04 , A61K45/06 , A61P31/12 , A61P31/22 , A61P31/14 , A61K31/4995

Abstract: The present invention relates to novel Heterocycle-Substituted Tetracyclic Compounds of Formula (I): (I) and pharmaceutically acceptable salts thereof, wherein A, A′, R2 R3 and R5 are as defined herein. The present invention also relates to compositions comprising at least one Heterocycle-Substituted Tetracyclic Compound, and methods of using the Heterocycle-Substituted Tetracyclic Compounds for treating or preventing HCV infection in a patient.

8.

发明申请
AMINOQUINAZOLINE COMPOUNDS AS A2A ANTAGONIST 审中-公开

公开(公告)号：US20180037554A1

公开(公告)日：2018-02-08

申请号：US15549242

申请日：2016-02-01

Applicant: Merck Sharp & Dohme Corp.

Inventor： Amjad Ali , Rongze Kuang , Yeon-Hee Lim , Michael Man-Chu Lo , Pauline C. Ting , Purakkattle Biju , Manuel de Lera Ruiz , Sylvia J. Degrado , Alexander L. Tung , Timothy J. Henderson , Liwu Hong , Jae-Hun Kim , Dong Won-Shik Kim , Joe Lee , Jie Wu , Heping Wu , Yushi Xiao , Tao Yu , Gang Zhou , Xiaohong Zhu , Kevin D. McCormick , Jayaram R. Tagat , Dong Xiao , Tanweer Khan , Jianhua Cao , Michael Berlin , Yonglian Zhang

IPC: C07D239/84 , C07D401/14 , C07D413/12 , C07D417/12 , C07D405/12 , C07D417/14 , C07D413/14 , C07D471/04 , C07D401/12 , C07D403/12

CPC classification number: C07D239/84 , A61K31/517 , A61P25/14 , C07D401/12 , C07D401/14 , C07D403/12 , C07D405/12 , C07D405/14 , C07D413/12 , C07D413/14 , C07D417/12 , C07D417/14 , C07D471/04

Abstract: The present invention is directed to compounds of generic formula I: or pharmaceutically acceptable salts thereof that are believed to be useful as an A2A-receptor antagonist.

9.

发明申请
HETEROBICYCLO-SUBSTITUTED [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES 审中-公开

公开(公告)号：US20170197991A1

公开(公告)日：2017-07-13

申请号：US15423238

申请日：2017-02-02

Applicant: Merck Sharp & Dohme Corp.

Inventor： Amjad Ali , Michael Man-Chu Lo , Yeon-Hee Lim , Andrew Stamford , Rongze Kuang , Paul Tempest , Younong Yu , Xianhai Huang , Timothy J. Henderson , Jae-Hun Kim , Christopher Boyce , Pauline Ting , Junying Zheng , Edward Metzger , Nicolas Zorn , Dong Xiao , Gioconda V. Gallo , Walter Won , Heping Wu , Qiaolin Deng

IPC: C07D519/00 , C07D487/04

CPC classification number: C07D519/00 , C07D487/04

Abstract: Disclosed are compounds of Formula G1: where “RG3”. “Rd1” to “Rd4”, “n”, “m”, “p”, “W”, “X”, “Y”, and “Z” are defined herein, which compounds are antagonists of A2A receptor. Disclosed herein also are uses of the compounds described herein as antagonists of the A2A receptor in the potential treatment or prevention of neurological disorders and diseases in which A2A receptors are involved. Disclosed herein also are pharmaceutical compositions comprising these compounds and uses of these pharmaceutical compositions.